<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032097</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069257</org_study_id>
    <secondary_id>NABTT-2116</secondary_id>
    <secondary_id>JHOC-NABTT-2116</secondary_id>
    <nct_id>NCT00032097</nct_id>
  </id_info>
  <brief_title>Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain</brief_title>
  <official_title>A Phase I Trial To Evaluate Repetitive Intravenous Doses Of Gadolinium-Texaphyrin As A Radiosensitizer In Patients With Glioblastoma Multi Forme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as&#xD;
      motexafin gadolinium may make the tumor cells more sensitive to radiation therapy.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness motexafin gadolinium in treating patients&#xD;
      with glioblastoma multiforme who are undergoing radiation therapy to the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity of 2 different schedules of motexafin gadolinium as a&#xD;
           radiosensitizer in patients with glioblastoma multiforme receiving cranial radiotherapy.&#xD;
&#xD;
        -  Determine the maximum tolerated doses of this drug on these 2 schedules in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the biodistribution of this drug in both neoplastic tissue and normal brain&#xD;
           parenchyma in these patients.&#xD;
&#xD;
        -  Determine the effect and accumulation of this drug in both normal brain parenchyma and&#xD;
           neoplastic tissue in these patients.&#xD;
&#xD;
        -  Correlate the effect and accumulation of this drug in both normal brain parenchyma and&#xD;
           neoplastic tissue with the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of motexafin gadolinium (PCI-0120).&#xD;
      Patients are sequentially assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group I: Patients receive PCI-0120 IV over 30-60 minutes once every other day for 6&#xD;
           weeks. Patients concurrently undergo cranial radiotherapy once daily 5 days a week for 6&#xD;
           weeks.&#xD;
&#xD;
        -  Group II: Patients receive PCI-0120 IV over 30-60 minutes once daily concurrently during&#xD;
           radiotherapy. Patients undergo cranial radiotherapy as in group I.&#xD;
&#xD;
      Cohorts of 3-6 patients in each group receive escalating doses of PCI-0120 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1 month and then every 2 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial grade IV astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Previously untreated disease&#xD;
&#xD;
          -  Measurable and contrast-enhancing tumor by MRI after incomplete resection/biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT no greater than 4 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 4 times ULN&#xD;
&#xD;
          -  PT/APTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Mini mental state exam score at least 15&#xD;
&#xD;
          -  No history of glucose-6-phosphate dehydrogenase deficiency or porphyria&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of&#xD;
             the breast&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No other medical illness that would preclude study participation&#xD;
&#xD;
          -  No allergy to MRI contrast (e.g., motexafin gadolinium)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 2 months after&#xD;
             study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy or immunotherapy for this disease, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Immunotoxins&#xD;
&#xD;
               -  Immunoconjugates&#xD;
&#xD;
               -  Antisense therapy&#xD;
&#xD;
               -  Peptide receptor antagonists&#xD;
&#xD;
               -  Interferons&#xD;
&#xD;
               -  Interleukins&#xD;
&#xD;
               -  Tumor-infiltrating lymphocytes&#xD;
&#xD;
               -  Lymphokine-activated killer cell therapy&#xD;
&#xD;
               -  Gene therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for this disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Must be on a stable corticosteroid regimen (i.e., no increase within 5 days prior to&#xD;
             treatment on this protocol)&#xD;
&#xD;
          -  No other prior hormonal therapy for this disease&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for this disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L. Pearlman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2004</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

